

Corporate Office, Court de la ACME, 1/4, Kallayanpur, Mirpur Road, Dhaka -1207. Web: www.acmeglobal.com

PRICE SENSITIVE INFORMATION

This is for the information of all concerned that the Board of Directors of **The ACME Laboratories Ltd.** in its **154**th **Meeting** held on **Tuesday**, the **30 January 2024** at **4.00 P.M.** through Digital Platform has approved the Second Quarter (Q2) Un-Audited Financial Statements of the Company for the period ended 31 December 2023 and disclosed the following financial indicators of the Company:

(Amount in BDT)

Particulars		As at 31 December 2023		As at 30 June 2023	
i) Net Asset Value (NAV) (in million)	:	23,820.46		23295.12	
ii) Net Asset Value Per Share (NAVPS)	:	112.57		110.09	
		From 01 July 2023 to 31 December 2023	From 01 July 2022 to 31 December 2022	From 01 October 2023 to 31 December 2023	From 01 October 2022 to 31 December 2022
iii) Net Profit After Tax (in million)	:	1,223.46	1,152.66	564.89	532.85
iv) Earnings Per Share (EPS)	:	5.78	5.45	2.67	2.52
v) Net Operating Cash Flow Per Share (NOCFPS)	:	5.02	6.09		

The details of the Second Quarter (Q2) Un-Audited Financial Statements for the period ended 31 December 2023 are available in the website of the Company at www.acmeglobal.com

Dated: **Dhaka**

30 January 2024

By the order of the Board Sd/-

Masudur Rahman Bhuiyan, Fcs Company Secretary